Author's response to reviews

**Title:** monitoring the efficacy and safety of three artemisinin combinations therapies (ACT) in Senegal: results from two years surveillance

**Authors:**

  khadime SYLLA (khadimesylla@yahoo.fr)
  Annie Abiola (annie_abiola@yahoo.fr)
  Roger Clement Kouly Tine (rogertine@hotmail.com)
  Babacar Faye (bfaye67@yahoo.fr)
  Doudou Sow (doudsow@yahoo.fr)
  Jean Louis Ndiaye (jlniaye@yahoo.com)
  Magatte Ndiaye (magou22000@yahoo.fr)
  Amy Cole Lo (amlosn@yahoo.fr)
  Kuaku Folly (jkfaro@yahoo.fr)
  Oumar Gaye (ogaye@refer.sn)

**Version:** 4  **Date:** 30 May 2013

**Author's response to reviews:** see over
Dear Editor

One behalf of my coauthors, I make the changes requested by the editorial team of *BMC infectious diseases* on the manuscript entitled “monitoring the efficacy and safety of three artemisinin combinations therapies (ACT) in Senegal: results from two years surveillance” to be considered for publication in *BMC Infectious Diseases.*

I made all the necessary changes to the english, the registration number and informed consent.

The study was conducted by the department of Parasitology-Mycology of the faculty of Medicine of University of Dakar which is responsible for the monitoring of the artemisinin combination therapy for malaria *Plasmodium falciparum* treatment in Senegal.

The main aim of this study was to monitor the efficacy and the safety of three artemisinin combination therapy in Senegal after several years of large use and after the recent emergence *Pf* susceptibility reduction on ACT in Asia. Our results clearly show that dihydro-artemisinine-piperaquine DHAPQ (Duocotexcin®), artemether-lumefantrine AL (Coartem®) and artesunate-amodiaquine ASAQ are effectious and well tolerated for malaria treatment in Senegal mainly in West Africa.

There is no conflict of interest in connection with this paper and the material has not been published and will not be submitted for publication elsewhere so long as it is under consideration by the *BMC Infectious Diseases.* While believing that this paper may be of interest for the general reader of the *BMC Infectious Diseases,* we remain at your disposal for any further information.

Dr Khadime SYLLA